2023
Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation
Pekayvaz K, Gold C, Hoseinpour P, Engel A, Martinez-Navarro A, Eivers L, Coletti R, Joppich M, Dionísio F, Kaiser R, Tomas L, Janjic A, Knott M, Mehari F, Polewka V, Kirschner M, Boda A, Nicolai L, Schulz H, Titova A, Kilani B, Lorenz M, Fingerle-Rowson G, Bucala R, Enard W, Zimmer R, Weber C, Libby P, Schulz C, Massberg S, Stark K. Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation. Immunity 2023, 56: 2325-2341.e15. PMID: 37652021, PMCID: PMC10588993, DOI: 10.1016/j.immuni.2023.08.002.Peer-Reviewed Original ResearchChronic inflammationVascular macrophagesPersistent tissue injuryChronic inflammatory diseaseSmooth muscle cellsMacrophage nicheInflammation contributesChemokine CCL2Inflammatory diseasesPlaque areaTissue injuryVascular bedPlaque necrosisMacrophage phenotypeAdvanced stageHomeostatic functionsNecrotic coreMuscle cellsInflammationAtherosclerosisMacrophagesMural cellsIntravital imagingProtective nicheNecrotic cellsA pref-1-controlled non-inflammatory mechanism of insulin resistance
Huang Y, Cui D, Chen L, Tong H, Wu H, Muller G, Qi Y, Wang S, Xu J, Gao X, Fifield K, Wang L, Xia Z, Vanderluit J, Liu S, Leng L, Sun G, McGuire J, Young L, Bucala R, Qi D. A pref-1-controlled non-inflammatory mechanism of insulin resistance. IScience 2023, 26: 106923. PMID: 37283810, PMCID: PMC10239698, DOI: 10.1016/j.isci.2023.106923.Peer-Reviewed Original ResearchInsulin resistanceMIF secretionPref-1 expressionPref-1Fat-induced insulin resistancePlasma MIF levelsNon-inflammatory mechanismsActivation of PAR2Palmitic acid dietHigh fat-induced insulin resistanceWhite adipose tissueSubsequent insulin resistanceMIF levelsPAR2 expressionM2 macrophagesAcid dietAdipose tissueAMPK-dependent mannerEndothelial cellsSecretionIntegrin β1CellsExpressionHigh levelsInflammation
2020
Designed CXCR4 mimic acts as a soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting
Kontos C, El Bounkari O, Krammer C, Sinitski D, Hille K, Zan C, Yan G, Wang S, Gao Y, Brandhofer M, Megens RTA, Hoffmann A, Pauli J, Asare Y, Gerra S, Bourilhon P, Leng L, Eckstein HH, Kempf WE, Pelisek J, Gokce O, Maegdefessel L, Bucala R, Dichgans M, Weber C, Kapurniotu A, Bernhagen J. Designed CXCR4 mimic acts as a soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting. Nature Communications 2020, 11: 5981. PMID: 33239628, PMCID: PMC7689490, DOI: 10.1038/s41467-020-19764-z.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnimalsAntigens, CDAtherosclerosisBinding SitesCarotid Artery, CommonChemokine CXCL12Crystallography, X-RayDisease Models, AnimalDrug DesignDrug Evaluation, PreclinicalEndarterectomy, CarotidFemaleHumansIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMaleMiceMice, Knockout, ApoEMiddle AgedPeptide FragmentsReceptors, CXCR4SialyltransferasesSignal TransductionConceptsMacrophage migration inhibitory factorCXC motif chemokine receptor 4Chemokine receptorsChemokine/receptor axisCXCR4/CXCL12 interactionHuman carotid endarterectomy specimensMigration inhibitory factorChemokine receptor 4MIF/CD74Carotid endarterectomy specimensAtherogenic inflammationCXCL12 interactionReceptor axisReceptor 4MIF inhibitorsReceptor-based strategiesAtherosclerotic plaquesAtherosclerosisAtypical chemokineLeukocyte adhesionCell activityProtective pathwaysInflammationChemokinesPlaques
2017
FRI-393 Macrophage migration inhibitory factor (MIF) modulates T-cell proliferation and hepatic inflammation in a model of autoimmune liver disease
Roberts S, Leng L, Soroka C, Boyer J, Bucala R, Assis D. FRI-393 Macrophage migration inhibitory factor (MIF) modulates T-cell proliferation and hepatic inflammation in a model of autoimmune liver disease. Journal Of Hepatology 2017, 66: s363-s364. DOI: 10.1016/s0168-8278(17)31067-x.Peer-Reviewed Original Research
2010
P81 MIF-DEFICIENCY REDUCES CHRONIC INFLAMMATION IN ADIPOSE TISSUE AND IMPAIRS INSULIN RESISTANCE AND ASSOCIATED ATHEROSCLEROSIS IN A MODEL OF COMBINED DISEASE
Kleemann R, Verschuren L, Wielinga P, Voshol P, van Erk M, Fingerle-Rowson G, van Dijk K, Ouwens M, Bernhagen J, Bucala R, Kooistra T. P81 MIF-DEFICIENCY REDUCES CHRONIC INFLAMMATION IN ADIPOSE TISSUE AND IMPAIRS INSULIN RESISTANCE AND ASSOCIATED ATHEROSCLEROSIS IN A MODEL OF COMBINED DISEASE. Atherosclerosis Plus 2010, 11: 33. DOI: 10.1016/s1567-5688(10)70148-3.Peer-Reviewed Original Research
2003
Chapter 45 Macrophage migration inhibitory factor (MIF)
Arenberg D, Bucala R. Chapter 45 Macrophage migration inhibitory factor (MIF). 2003, II: 1037-xxxiii. DOI: 10.1016/b978-012689663-3/50049-1.Peer-Reviewed Original ResearchMacrophage migration inhibitory factorMigration inhibitory factorRegulation of MIFCritical pro-inflammatory mediatorInhibitory factorPro-inflammatory mediatorsMIF receptorImmune cellsImmunosuppressive propertiesCellular proliferationWidespread expressionMediatorsFuture investigationsCellsInflammationCytokinesGlucocorticoidsPathogenesisSteroidsSecretionActivityImportant roleReceptors